Skip to content

REDUNING, a kind of traditional Chinese medicine injections, in the treatment of human H7N9 bird flu: A single-center, randomized, open, controlled clinical trial

REDUNING, a kind of traditional Chinese medicine injections, in the treatment of bird flu: A single-center, randomized, open, controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006047
Enrollment
Unknown
Registered
2015-03-06
Start date
2015-02-25
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H7N9 bird flu

Interventions

test group:Peramivir injection+REDUNING injection
control group:Peramivir injection

Sponsors

First Affiliated Hospital, College of Medcine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) conform to diagnostic criteria of "human infection with the H7N9 bird flu clinic program (2014 Edition)" issued by National Health Planning Commission issued the general office ; (2) the result of human infection with the H7N9 virus nucleic acid detection is positive; (3) axillary temperature less than 38.5?; (4) subjects age are from 18~75 years old; (5) the course is in 1 week; (6) patients need to be in hospital judged by researchers; (7) patients who muse be voluntary to the trail and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) immunodeficiency disease, or within the past 3 months, the use of immunosuppressants or glucocorticoid; (2) prepare for lactation pregnancy, pregnant women and women; (3) allergy (allergic to more than two kinds of drugs or food or known component of the trial drug); (4) psychotic patients without self-knowledge ability; (5) patients are not expected to survival within 48h from screening; (6) tracheal intubation, mechanical ventilation from screening; (7) patients are not suitable to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
Time of temperature to nomal;the rate of clinical symptom improvement and clinical symptom disappearance time;use of hormone;rate of mechanical ventilation;the mortality rate;the time of of human infection with the H7N9 avian influenza virus nucleic acid from positive to negative;the number of days of hospitalization / ICU stay days;

Countries

China

Contacts

Public ContactGao Hainv
gaohainv@163.com+86 13957163067

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026